SEC Tracker
Get the app
SLS · XBRL financial data

SELLAS Life Sciences Group financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (SLS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers00*——————————
Cost of goods and services sold00*0000*0000*00*
Selling, general and administrative3,5483,080*4,5342,4352,9672,481*2,8583,0022,8673,525*——
General and administrative——————2,8583,002——4,1234,357
Operating income (loss)(9,361)(8,177)*(9,645)(7,621)(7,329)(6,918)*(6,063)(6,873)(7,083)(8,255)*(9,252)(10,629)
Income tax expense (benefit)—year only———year only———year only——
Net income (loss)(9,267)(8,136)*(9,566)(7,470)(7,108)(6,737)*(5,813)(6,601)(6,791)(7,658)*(8,407)(9,605)
Earnings per share, basic USD per share(0.33)(0.26)*(0.21)(0.13)(0.10)(0.09)*(0.07)(0.07)(0.06)—(0.05)(0.05)
Earnings per share, diluted USD per share(0.33)(0.26)*(0.21)(0.13)(0.10)(0.09)*(0.07)(0.07)(0.06)—(0.05)(0.05)
Weighted average shares, basic thousands of shares28,35530,772*44,81357,63168,25473,895*87,76098,559108,396—172,482189,184
Weighted average shares, diluted thousands of shares28,35530,772*44,81357,63168,25473,895*87,76098,559108,396—172,482189,184

Balance sheet

CSV

Fiscal quarters (SLS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents3,9692,53018,4159,14721,03113,88628,39725,29744,32071,793107,097138,343
Prepaid and other current assets1,1345422,9863,0552,9042,3413,4764,0504,6313,3183,9724,062
Total current assets5,2033,17221,50112,30224,03516,32731,97329,44749,05175,211111,169142,505
Right-of-use asset592858747633513925806683556963839710
Goodwill1,9141,9141,9141,9141,9141,9141,9141,9141,9141,9141,9141,914
Total assets8,0866,21924,43415,11926,50519,43234,95632,30551,55578,345114,177145,382
Accounts payable4,3405,6397,4076,3314,5473,5003,7563,3362,3052,9483,6333,086
Accrued liabilities6,9297,6506,5425,1835,4905,4662,5712,0833,0213,5252,2613,903
Total current liabilities11,73513,73514,43712,04510,6139,5106,8885,9995,9257,0176,4567,569
Lease liability, non-current17846031316104573091570457309157
Total liabilities11,91314,19514,75012,20610,6139,9677,1976,1565,9257,4746,7657,726
Accumulated deficit(209,108)(217,244)(226,810)(234,280)(241,388)(248,125)(253,938)(260,539)(267,330)(274,988)(283,395)(293,000)
Total stockholders' equity(3,827)(7,976)9,6842,91315,8929,46527,75926,14945,63070,871107,412137,656
Total liabilities and equity8,0866,21924,43415,11926,50519,43234,95632,30551,55578,345114,177145,382
Common shares outstanding (cover page) thousands of shares32,06256,26857,75564,33270,38290,84799,777105,297142,442179,583186,033201,946

Cash flows

CSV

Fiscal quarters (SLS's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(9,267)(8,136)*(9,566)(7,470)(7,108)(6,737)*(5,813)(6,601)(6,791)(7,658)*(8,407)(9,605)
Stock-based compensation543*497*476334*381*373*505501*503*447*7981,015*
Net cash from operating activities(6,892)*(4,825)*(10,761)(9,682)*(7,806)*(7,153)*(9,070)(7,330)*(7,068)*(4,921)*(8,846)(7,588)*
Net cash from investing activities(3,000)*0*——0*0*——————
Proceeds from issuing common stock0*21*00*0*0*——————
Net cash from financing activities54*3,386*26,646414*19,690*8*23,5814,230*26,091*32,394*44,15038,834*
Net change in cash(9,838)*(1,439)*15,885(9,268)*11,884*(7,145)*14,511(3,100)*19,023*27,473*35,30431,246*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
SELLAS Life Sciences Group138,343not reported(7,588)*201.9M18.2 quarters 10-QJun 30, 2026
Precigen16,32954,978(17,809)*358.0M2.1 quarters 10-QJun 30, 2026
Lifecore Biomedical17,241not reported(2,189)*37.9M7.9 quarters 10-QJun 30, 2026
Perspective Therapeutics48,488not reported(20,650)*114.2M11.5 quarters 10-QJun 30, 2026
Rocket Pharmaceuticals224,5070(39,613)*109.8M7.2 quarters 10-QJun 30, 2026
Natures Sunshine Products82,503116,985835*17.6M— 10-QJun 30, 2026
Sagimet Biosciences165,896not reported(11,099)*not reported21.6 quarters 10-QJun 30, 2026
Tvardi Therapeutics15,765not reported(9,228)*13.3M1.7 quarters 10-QJun 30, 2026
Aldeyra Therapeutics45,090not reported(4,589)*60.3M9.8 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.